Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Sci Rep ; 13(1): 14606, 2023 09 05.
Artigo em Inglês | MEDLINE | ID: mdl-37670132

RESUMO

This study introduces a simple method for preparing a new generation of MnO2 nanomaterials (MNMs) using tannic acid as a template. Two shapes of MnO2 NMs, flower-like M1-MnO2 and near-spherical M2-MnO2, were prepared and compared as dual-active nanozymes and contrast agents in magnetic resonance imaging (MRI). Various parameters, including the crystallinity, morphology, magnetic saturation (Ms), surface functionality, surface area, and porosity of the MNMs were investigated. Flower-like M1-MnO2 NMs were biocompatible and exhibited pH-sensitive oxidase and peroxidase mimetic activity, more potent than near-spherical M2-MnO2. Furthermore, the signal intensity and r1 relaxivity strongly depended on the crystallinity, morphology, pore size, and specific surface area of the synthesized MNMs. Our findings suggest that flower-like M1-MnO2 NM with acceptable dual-enzyme mimetic (oxidase-like and peroxidase-like) and T1 MRI contrast activities could be employed as a promising theranostic system for future purposes.


Assuntos
Meios de Contraste , Nanoestruturas , Compostos de Manganês , Óxidos , Peroxidase , Imageamento por Ressonância Magnética , Peroxidases
2.
ACS Appl Mater Interfaces ; 15(36): 42251-42270, 2023 Sep 13.
Artigo em Inglês | MEDLINE | ID: mdl-37647536

RESUMO

Dysfunctional clinical outcomes following spinal cord injury (SCI) result from glial scar formation, leading to the inhibition of new axon growth and impaired regeneration. Nevertheless, nerve regeneration after SCI is possible, provided that the state of neuron development in the injured environment is improved. Hence, biomaterial-based therapy would be a promising strategy to endow a desirable environment for tissue repair. Herein, we designed a novel multifunctional injectable hydrogel with antioxidant, neuroprotective, and neuroregenerative effects. Bucladesine-encapsulated chitosan nanoparticles (BCS NPs) were first prepared and embedded in a matrix of thiol-functionalized hyaluronic acid modified with ferulic acid (HASH-FA). The target hydrogel (HSP-F/BCS) was then created through Michael-type addition between HASH-FA containing BCS NPs and four-arm polyethylene glycol-maleimide (4-Arm-PEG-Mal). The obtained hydrogel with shear thinning behavior showed viscoelastic and mechanical properties similar to the normal nerve tissue. FA conjugation significantly improved the antioxidant activity of HA, and suppressed intracellular ROS formation. In situ injection of the HSP-F/BCS hydrogel in a rat contusion model of SCI inhibited glial scar progression, reduced microglia/macrophage infiltration, promoted angiogenesis, and induced myelinated axon regeneration. As a result, a significant improvement in motor performance was observed compared to other experimental groups. Taken together, the HSP-F/BCS hydrogel developed in this study could be a promising system for SCI repair.


Assuntos
Traumatismos da Medula Espinal , Regeneração da Medula Espinal , Animais , Ratos , Bucladesina , Axônios , Gliose , Traumatismos da Medula Espinal/tratamento farmacológico , Antioxidantes/farmacologia , Hidrogéis/farmacologia
3.
Mini Rev Med Chem ; 22(2): 273-311, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-33687881

RESUMO

Due to the high mortality rate of the 2019 coronavirus disease (COVID-19) pandemic, there is an immediate need to discover drugs that can help before a vaccine becomes available. Given that the process of producing new drugs is so long, the strategy of repurposing existing drugs is one of the promising options for the urgent treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19 disease. Although FDA has approved Remdesivir for the use in hospitalized adults and pediatric patients suffering from COVID-19, no fully effective and reliable drug has been yet identified worldwide to treat COVID-19 specifically. Thus, scientists are still trying to find antivirals specific to COVID-19. This work reviews the chemical structure, metabolic pathway, and mechanism of action of the existing drugs with potential therapeutic applications for COVID-19. Furthermore, we summarized the molecular docking stimulation of the medications related to key protein targets. These already established drugs could be further developed, and after their testing through clinical trials, they could be used as suitable therapeutic options for patients suffering from COVID-19.


Assuntos
Antivirais/farmacologia , Tratamento Farmacológico da COVID-19 , COVID-19/virologia , Redes e Vias Metabólicas/efeitos dos fármacos , SARS-CoV-2/efeitos dos fármacos , SARS-CoV-2/metabolismo , Antivirais/uso terapêutico , Humanos , Simulação de Acoplamento Molecular , SARS-CoV-2/crescimento & desenvolvimento , SARS-CoV-2/patogenicidade
4.
Infect Genet Evol ; 90: 104773, 2021 06.
Artigo em Inglês | MEDLINE | ID: mdl-33607284

RESUMO

The third pandemic of coronavirus infection, called COVID-19 disease, was first detected in November 2019th. Various determinants of disease progression such as age, sex, virus mutations, comorbidity, lifestyle, host immune response, and genetic background variation have caused clinical variability of COVID-19. The causative agent of COVID-19 is an enveloped coronavirus named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that invades host cells using an endocytic pathway. The SARS-CoV-2 spike protein is the main viral protein that contributes to the fusion of the virus particle to the host cell through angiotensin-converting enzyme 2 (ACE2). The highly conserved expression of ACE2 is found in various animals, which indicates its pivotal physiological function. The ACE2 has a crucial role in vascular, renal, and myocardial physiology. Genetic factors contributing to the outcome of SARS-CoV-2 infection are unknown; however, variants in the specific sites of ACE2 gene could be regarded as a main genetic risk factor for COVID-19. Given that ACE2 is the main site for virus landing on host cells, the effect of amino acid sequences of ACE2 on host susceptibility to COVID-19 seems reasonable. It would likely have a substantial role in the occurrence of a wide range of clinical symptoms. Several ACE2 variants can affect the protein stability, influencing the interaction between spike protein and ACE2 through imposing conformational changes while some other variants are known to cause a decrease or an increase in the ligand-receptor affinity. The other variations are located at the proteolytic cleavage site, which can influence virus infection; because soluble ACE2 can act as a decoy receptor for virus and decrease virus intake by cell surface ACE2. Notably, polymorphisms of regulatory and non-coding regions such as promoter in ACE2, can play crucial role in different expression levels of ACE2 among different individuals. Many studies should be performed to investigate the involvement of ACE2 polymorphism with susceptibility to COVID-19. Herein, we discuss some reported associations between variants of ACE2 and COVID-19 in details. In addition, the mode of action of ACE2 and its role in SARS-CoV-2 infection are highlighted which is followed by addressing the effects of several ACE2 variants on its protein stability, viral tropism or ligand-receptor affinity, secondary and tertiary structure or protein conformation, proteolytic cleavage site, and finally inter-individual clinical variability in COVID-19. The polymorphisms of regulatory regions of ACE2 and their effect on expression levels of ACE2 are also provided in this review. Such studies can improve the prediction of the affinity of mutant ACE2 variations with spike protein, and help the biopharmaceutical industry to design effective approaches for recombinant hACE2 therapy and vaccination of COVID-19 disease.


Assuntos
Enzima de Conversão de Angiotensina 2/genética , COVID-19/genética , COVID-19/virologia , Suscetibilidade a Doenças , Variação Genética , Interações Hospedeiro-Patógeno , SARS-CoV-2/fisiologia , Enzima de Conversão de Angiotensina 2/metabolismo , COVID-19/diagnóstico , COVID-19/metabolismo , Síndrome da Liberação de Citocina/etiologia , Síndrome da Liberação de Citocina/metabolismo , Gerenciamento Clínico , Interações Hospedeiro-Patógeno/imunologia , Humanos , Evasão da Resposta Imune , Imunidade Inata , Polimorfismo de Nucleotídeo Único , Prognóstico , Ligação Proteica , Receptores Virais/metabolismo , Índice de Gravidade de Doença
5.
Int J Biol Macromol ; 148: 1118-1129, 2020 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-31982534

RESUMO

spinal cord injury (SCI) is a traumatic damage that can causes a loss of neurons around the lesion site and resulting in locomotor and sensory deficits. Currently, there is widely attempts in improvement of treatment strategy and cell delivering to the central nervous system (CNS). The usage of hyaluronic acid (HA), the main components of the ECM in CNS tissue and neural stem cells (NSCs) niche, is a good selection that can increase of viability and differentiation of NSCs. Importantly, we demonstrate that encapsulation of human embryonic stem cell derived-neural stem cells (hESC-NS) in HA-based hydrogel can increased differentiation these cells into oligodendrocytes and improved locomotor function.


Assuntos
Diferenciação Celular , Células-Tronco Embrionárias Humanas/citologia , Ácido Hialurônico , Células-Tronco Neurais/citologia , Regeneração , Transplante de Células-Tronco , Animais , Sobrevivência Celular , Células Cultivadas , Gerenciamento Clínico , Imunofluorescência , Células-Tronco Embrionárias Humanas/metabolismo , Humanos , Hidrogéis , Masculino , Células-Tronco Neurais/metabolismo , Ratos , Traumatismos da Medula Espinal/terapia , Alicerces Teciduais
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...